Retinal Toxicity of Anticancer Drugs: A Case Series

Nicolò Bartolomeo; Alexandre Déglise; Yannic Pannatier Schuetz; Daniela Gallo Castro; Anna Chiara Nascimbeni; Aude Ambresin

doi:10.1055/a-2521-4104

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2025; 242(04): 429-431
DOI: 10.1055/a-2521-4104

Der interessante Fall

Retinal Toxicity of Anticancer Drugs: A Case Series

Retinale Toxizität von Krebsmedikamenten: eine Fallserie

Nicolò Bartolomeo

¹Ophthalmology, Swiss Visio Montchoisi, Lausanne, Switzerland

,

Alexandre Déglise

¹Ophthalmology, Swiss Visio Montchoisi, Lausanne, Switzerland

,

Yannic Pannatier Schuetz

¹Ophthalmology, Swiss Visio Montchoisi, Lausanne, Switzerland

,

Daniela Gallo Castro

¹Ophthalmology, Swiss Visio Montchoisi, Lausanne, Switzerland

,

Anna Chiara Nascimbeni

¹Ophthalmology, Swiss Visio Montchoisi, Lausanne, Switzerland

,

Aude Ambresin

¹Ophthalmology, Swiss Visio Montchoisi, Lausanne, Switzerland

²Faculty of Biology and Medicine, University of Lausanne, Switzerland

› Author Affiliations

Abstract

Full Text

References

References
1 Swiss Government. Swiss Cancer Report 2021: Rise in number of cancer patients coincides with decline in mortality. https://www.admin.ch/gov/en/start/documentation/media-releases.msg-id-85462.html Accessed: 22.01.2025
2 Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med 2022; 54: 1670
3 Nakao S, Ikeda Y, Emi Y. et al. Possibility of Müller cell dysfunction as the pathogenesis of paclitaxel maculopathy. Ophthalmic Surg Lasers Imaging Retina 2016; 47: 81-84
4 Malcolm J, Lune Wong CO, Ching J. et al. Paclitaxel may be a risk factor for retinal phototoxicity. Am J Ophthalmol Case Rep 2022; 25: 101292
5 Schorr C, Forindez J, Espinoza-Gutarra M. et al. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies. Int J Mol Sci 2023; 24: 8349
6 Omoti AE, Omoti CE. Ophthalmic manifestations of multiple myeloma. West Afr J Med 2007; 26: 265-268
7 Dong LF, Yao J, Wang XQ. et al. Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder. Biochem Biophys Res Commun 2015; 465: 678-684
8 Van Dijk EHC, Duits DEM, Versluis M. et al. Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients. Medicine (Baltimore) 2016; 95: e3457
9 Jiang Q, Cao C, Lu S. MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med 2009; 23: 771-777
10 Huang S, Guo Z, Wang M. et al. Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system. Expert Opin Drug Saf 2023; 22: 175-181